Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES
GLOBETECH PUBLISHING

Qualitative Anti-HCV Immunoassay Test Designed for Use on Three Analyzer Platforms

By Labmedica International staff writers
Posted on 23 Jun 2010
A new hepatitis C virus (anti-HCV) assay is an 18-minute test designed for use with electrochemiluminescence (ECL) technology. Assay results, in conjunction with other laboratory results and clinical data, may be used to aid in the presumptive diagnosis of HCV infection in persons with signs and symptoms of hepatitis and in persons at risk for hepatitis C infection.

Roche Diagnostics Corp. (Basel, Switzerland) announced that the U.S. Food and Drug Administration (FDA) granted Premarket Approval for its Elecsys Antibody to anti-HCV assay. The Elecsys Anti-HCV assay is an in vitro diagnostic test for the qualitative detection of total antibodies to hepatitis C virus in human serum or plasma using Roche's ECL technology.

Roche received approvals for its test on three platforms: the stand-alone cobas e 411 analyzer for low-volume testing; and the Cobas e 601, and Modular Analytics E 170 analyzers, which are modules of consolidated immunoassay/clinical chemistry systems for mid- and high-volume testing, respectively. The test does not determine the state of infection or associated disease.

Roche received FDA 510(k) clearance for another immunoassay in its infectious disease portfolio, Rubella IgM, in April 2010.

Hepatitis C virus is the most common cause of posttransfusion and community-acquired non-A, non-B hepatitis worldwide. Infection with HCV frequently leads to chronic hepatitis and cirrhosis, and is associated with the development of hepatocellular carcinoma. Hepatitis C is primarily transmitted through contaminated blood and blood products and to a lower extent by human body secretions.

Roche is involved in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with differentiated medicines in oncology, virology, inflammation, metabolism, and the central nervous system (CNS).

Related Links:

Roche Diagnostics



PURITAN MEDICAL
Sekisui Diagnostics
EUROIMMUN AG
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: Enzyme-linked immunosorbent kit (ELISA) specific for human copeptin (Photo courtesy of USCN Life Science).

Preeclampsia Biomarker Detected Very Early In Pregnancy

A biomarker has been discovered that could give expecting mothers and their doctors the first simple blood test to reliably predict that a pregnant woman may develop preeclampsia, at least as early as... Read more

Pathology

view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

Brain Tumor Chemotherapy Biomarkers Identified

Cancer researchers have identified a new biomarker that they believe can predict whether glioblastoma multiformes (GBMs), the most common and aggressive type of malignant brain tumor, will be susceptible... Read more

Industry News

view channel

EKF Wins Distribution Contract and Regulatory Approval for Target Regions

EKF Diagnostics Holdings (Cardiff, Wales, UK), an AIM-listed point-of-care, central laboratory and molecular diagnostics business, announced that it has signed a new distribution contract in China and that one of its OEM (original equipment manufacturer) partners has received further regulatory approval across several target... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.